Advancing Novel Medical Isotopes for Clinical Trials | DE FOA 0002532

Frequently Asked Questions (FAQs)

What is the purpose of this DOE funding opportunity?

This grant opportunity from the Department of Energy (DOE) Office of Science, through the Isotope Research and Development and Production program (DOE IP), is intended to speed up the "bench-to-clinic" pipeline for newly developed medical radioisotopes. The focus is on research that removes technical bottlenecks so DOE-developed isotopes and enabling chemistry can be prepared in a form that is ready for downstream pre-clinical and clinical trial consideration by appropriate entities.

What does "bench-to-clinic" mean in this funding context?

Here, "bench-to-clinic" refers to the practical translation steps between laboratory isotope development/production and having a usable, distributable material package suitable to hand off for biological or clinical evaluation. The program aims to make translation easier, faster, and more reliable by funding work that improves readiness, not the medical evaluation itself.

What kinds of projects are in scope?

Projects are expected to focus on translational-enabling research tied to recently developed DOE IP medical isotopes (as listed in the FOA). Example areas include developing or improving chelating agents, linker/ligand systems, labeling methods, purification strategies, and quality control approaches that help ensure the isotope can be prepared and provided in a medically relevant, usable form for downstream evaluation.

Are chelators, linkers, and ligands part of the intended research?

Yes. The opportunity explicitly highlights enabling chemistry such as chelating agents and linker/ligand systems. It is flexible regarding the specific chelator and ligand technology used with eligible isotopes, recognizing that chelation and targeting chemistry can strongly affect stability in vivo, safety of formulation, and delivery to biological targets for imaging or therapy.

What is explicitly out of scope and will not be funded?

The opportunity does not fund the actual evaluation of isotopes, chelators, or ligands in pre-clinical or clinical trials. Any application requesting support to conduct pre-clinical testing, clinical testing, or trial evaluation activities is out of scope and will be rejected without merit review.

What happens if a proposal includes pre-clinical or clinical trial work?

If a proposal requests support for pre-clinical testing, clinical testing, or trial evaluation activities, the funding announcement states it will be rejected without merit review.

Is basic isotope research eligible if it is not tied to translation?

No. Proposals focused on isotope R&D that is not connected to translational readiness (for example, basic isotope research without a clear path to preparing a usable, distributable, medically relevant material package) are considered out of scope and will be declined without merit review.

What is meant by "translational readiness" in this opportunity?

Translational readiness refers to the technical steps needed to move from a laboratory-produced isotope to a material and process package that is suitable for downstream biological or clinical evaluation by appropriate external entities. The goal is to remove bottlenecks and increase reliability so clinical-oriented organizations could realistically take the next steps.

Which isotopes are eligible for this opportunity?

The opportunity is limited to medical isotopes that have been recently developed by DOE IP. The specific eligible isotopes are listed in the Funding Opportunity Announcement (FOA) itself.

Does the opportunity allow flexibility in the chemistry approach used with the isotopes?

Yes. While isotope eligibility is limited to those listed in the FOA, the program is flexible regarding the chelator and ligand technology proposed to enable medical use, as long as the work is aimed at accelerating readiness for downstream trial consideration.

What types of bottlenecks is the DOE trying to remove?

Based on the announcement, bottlenecks include technical barriers between laboratory production and a form suitable for handoff for downstream evaluation. This can include challenges in labeling, formulation, purification, quality control, stability, and other practical translation steps that affect whether a material can be reliably prepared and distributed for later biomedical assessment.

Can projects include training components?

Yes. Applications that include strong approaches to training personnel are strongly encouraged, especially when training is tied to specialized, hands-on skills needed in isotope production and supply chains.

What kind of training is encouraged?

Training is encouraged in areas related to producing, processing, purifying, and distributing enriched stable isotopes and radioactive isotopes. The intent is to strengthen workforce capability and operational know-how that supports reliable isotope availability.

Who administers the program and who coordinates review?

The DOE IP administers the funding opportunity, and proposal assessment will be coordinated with the National Institutes of Health (NIH). This coordination is intended to align DOE-supported translational preparation with biomedical pathway expectations, while keeping the DOE-funded scope focused on enabling technology and materials readiness rather than clinical evaluation.

What is the Funding Opportunity Number for this grant?

The Funding Opportunity Number is DE-FOA-0002532.

What is the grant category or program classification?

The opportunity is categorized under science and technology research and development and is listed under CFDA 81.049.

What is the maximum award amount (award ceiling)?

The posting lists an award ceiling of $500,000.

When was the opportunity created and when did it close?

The creation date is June 1, 2021, and the original closing date is July 23, 2021.

Who is eligible to apply?

Eligible applicants include public and state-controlled institutions of higher education, private institutions of higher education, and other eligible entities as defined in the FOA.

What types of organizations is the opportunity designed to leverage?

The opportunity is designed to leverage specialized infrastructure and technical capabilities available at universities, non-profit research institutions, and DOE/NNSA National Laboratories to shorten development timelines and improve the likelihood that new diagnostic and therapeutic radioisotope tools can be advanced efficiently toward clinical-oriented evaluation by other organizations.

Is the DOE funding clinical trials through this opportunity?

No. The funding announcement is explicit that pre-clinical and clinical trial evaluation activities are outside the DOE IP mission for this program and are not supported under this opportunity.

What is the main intended outcome of funded projects?

The intended outcome is to advance promising DOE-developed medical isotopes and enabling chemistry toward a state where they are suitable to be considered for future pre-clinical and clinical trials by the appropriate health-focused agencies and clinical partners, without DOE funding those evaluations directly.